JP2006192282A - 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物 - Google Patents
親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物 Download PDFInfo
- Publication number
- JP2006192282A JP2006192282A JP2006020891A JP2006020891A JP2006192282A JP 2006192282 A JP2006192282 A JP 2006192282A JP 2006020891 A JP2006020891 A JP 2006020891A JP 2006020891 A JP2006020891 A JP 2006020891A JP 2006192282 A JP2006192282 A JP 2006192282A
- Authority
- JP
- Japan
- Prior art keywords
- implant
- release
- delivery device
- drug
- pharmaceutical delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Prostheses (AREA)
Abstract
【解決手段】眼病治療剤としてステロイド(特に、抗炎症剤デキサメタゾン)がPLGAコポリマー(ポリ乳酸/ポリグリコール酸コポリマー)のマトリックス中に分散されたインプラントであり、該インプラントはファイバー、シート、フィルム、微小球、球、円板、及びプラークからなる群から選ばれる形状を有する医薬デリバリー装置である。
【選択図】なし
Description
制御持続性薬剤放出のために処方される生物分解性インプラント。
活性成分の持続的放出を提供する固体の薬学的に活性なインプラントは、身体中で相対的に均一濃度の活性成分を提供し得る。インプラントは特に、特定の標的部位での局所的高濃度を長時間提供するのに有用である。これらの持続性放出形態は投与される薬剤の投与回数を低減し、伝統的薬剤療法に伴って認められる薬剤濃度のピーク及び谷間をなくす。生物分解性薬剤供給系の使用はさらに、効力の無くなったインプラントを標的部位から除去する必要がないという利点を有する。
米国特許第4,997,652 号及び第5,164,188 号は、眼性症状の治療のために眼の前眼房又は後区中に導入するための生物適合性インプラントを開示する。
制御持続性薬剤放出を提供するために処方される生物分解性インプラントに関する組成物及び方法を提供する。放出速度はインプラント中の疎水性及び親水性薬剤の組合せにより調節される。放出調節剤は、放出速度を加速又は遅延するよう作用する。任意に、調節剤は治療的活性薬剤である。本発明は、活性薬剤を限定放出プロフィールと組合せた持続性放出インプラントを提供する。
制御薬剤放出は、緩徐放出生物分解性インプラントの改良型処方物により達成される。インプラントからの薬剤の放出速度は、インプラントへの放出調節剤の付加により調節される。疎水性薬剤の放出はインプラント中の促進剤の含入により増大され、一方遅延剤が含まれて、親水性薬剤の放出速度を低減する。放出調節剤は生理学的に不活性であるか、又は治療的活性薬剤である。当該処方物としては、抗炎症薬、例えば眼に活性な薬剤と併用されるグルココルチコイド、NSAIDS等が挙げられる。
実験的使用
放出調製剤を用いない薬剤供給系(DDS)の製造及び試験
疎水性薬剤デキサメタソンの延長放出薬剤供給系からの放出を測定した。デキサメタソン及びポリ乳酸/ポリグリコール酸コポリマーを用いて、薬剤供給系を製造した。デキサメタソン粉末及びポリ乳酸ポリグリコール酸(PLGA)コポリマーの粉末を、50/50の比で十分混合した。よく混合した粉末を押出機中に充填し、95℃で 1時間加熱し、次いで20ゲージ開口部を通して押し出した。約100〜120 μg の6つのDDSを薬剤放出査定のために押出しフィラメントから切り離した。
上記と同様に薬剤供給系を製造したが、但し種々の濃度の親水性ヒドロキシプロピルメチルセルロース(HPMC)を放出調節剤として含有した。表1に示した薬剤、ポリマー及びHPMCの組合せを用いた。
薬学的活性放出調節剤を用いたDDSの製造及び試験
実施例1と同様に薬剤供給系を製造したが、但し薬学的活性親水性化合物であるシプロフロキサシンを放出調節剤として含有した。表2に示した薬剤、ポリマー及びHPMCの組合せを用いた。
複数放出調節剤を用いたDDSの製造及び試験
表3にしたがって、ヒドロキシメチルセルロース、シプロフロキサシン及びデキサメタソンを用いて薬剤供給系を処方した。
CMV感染の治療のための糖質コルチコイド及びガンシクロビルを用いた薬剤供給系(DDS)の製造及び試験
実施例1に記載されているように薬剤供給系を製造したが、但し放出調節剤として薬学的活性親水性化合物であるガンシクロビルを含有した。薬剤及びポリマーの組合せを以下に示す:
抗腫瘍治療のための糖質コルチコイド及び5−フルオロウラシルを用いた薬剤供給系(DDS)の製造及び試験
実施例1に記載されているように薬剤供給系を製造したが、但し放出調節剤として薬学的活性親水性化合物である5−フルオロウラシルを含有した。薬剤及びポリマーの組合せを以下に示す:
NSAID及びキノロンを用いた薬剤供給系(DDS)の製造及び試験
実施例1に記載されているように薬剤供給系を製造したが、但し放出調節剤として薬学的活性親水性化合物である5−フルオロウラシルを含有した。薬剤及びポリマーの組合せを以下に示す:
Claims (18)
- 生物分解性硝子体内医薬デリバリー装置であって:
眼の硝子体腔内に移植される生物分解性硝子体内インプラントを含み、ここで、当該インプラントは、生物分解性ポリマーとステロイドを含み、当該ステロイドは、上記硝子体腔内に移植された後少なくとも3日間、上記インプラントから上記硝子体内に放出される、前記医薬デリバリー装置。 - 前記インプラントが、PLGAコポリマーを含む、請求項1に記載の医薬デリバリー装置。
- 前記インプラントがデキサメタゾンを含む、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが、PLGAコポリマー・マトリックスと、当該マトリックス中に分散されたデキサメタゾンを含む、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが、前記硝子体内の移植部位の大きさと形状に釣り合う大きさをもつ、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが、0.05mm〜3mm間の直径、及び0.5mm〜10mm間の長さをもつ、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが、2μm〜4mm間の直径をもつ、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが、1mm〜3mmの直径をもつ、請求項7に記載の医薬デリバリー装置。
- 前記インプラントは、3mm〜10mm間の大きさである、請求項1に記載の医薬デリバリー装置。
- 前記インプラントは、エクストルージョン法により製造される、請求項1に記載の医薬デリバリー装置。
- 前記インプラントは、押出しフィラメントの一部である、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが、当該インプラントの少なくとも1重量%である量のステロイドを含む、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが、当該インプラントの少なくとも10重量%の量のステロイドを含む、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが、当該インプラントの80重量%以下の量のステロイドを含む、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが、当該インプラントの40重量%以下の量のステロイドを含む、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが50重量%のデキサメタゾンを含む、請求項1に記載の医薬デリバリー装置。
- 前記インプラントが、ファイバー、シート、フィルム、微小球、球、円板、及びプラークから成る群から選ばれる幾何形状を有する、請求項1に記載の医薬デリバリー装置。
- 請求項1に記載の生物分解性医薬デリバリー装置を複数個含む組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/459,134 US5869079A (en) | 1995-06-02 | 1995-06-02 | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8536741A Division JPH11506450A (ja) | 1995-06-02 | 1996-05-31 | 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010228763A Division JP2011005300A (ja) | 1995-06-02 | 2010-10-08 | 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006192282A true JP2006192282A (ja) | 2006-07-27 |
Family
ID=23823541
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8536741A Pending JPH11506450A (ja) | 1995-06-02 | 1996-05-31 | 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物 |
JP2006020891A Withdrawn JP2006192282A (ja) | 1995-06-02 | 2006-01-30 | 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物 |
JP2010228763A Pending JP2011005300A (ja) | 1995-06-02 | 2010-10-08 | 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8536741A Pending JPH11506450A (ja) | 1995-06-02 | 1996-05-31 | 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010228763A Pending JP2011005300A (ja) | 1995-06-02 | 2010-10-08 | 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物 |
Country Status (18)
Country | Link |
---|---|
US (9) | US5869079A (ja) |
EP (4) | EP1637164A3 (ja) |
JP (3) | JPH11506450A (ja) |
KR (1) | KR19990022212A (ja) |
CN (1) | CN1191492A (ja) |
AT (2) | ATE315409T1 (ja) |
AU (1) | AU721421B2 (ja) |
BR (1) | BR9608642A (ja) |
CA (2) | CA2222889C (ja) |
DE (1) | DE69635734T3 (ja) |
DK (1) | DK1477187T3 (ja) |
ES (2) | ES2256859T5 (ja) |
MY (1) | MY132179A (ja) |
PL (1) | PL323747A1 (ja) |
PT (1) | PT1477187E (ja) |
RU (1) | RU2175561C2 (ja) |
TW (1) | TW487580B (ja) |
WO (1) | WO1996038174A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010504822A (ja) * | 2006-09-29 | 2010-02-18 | サーモディクス,インコーポレイティド | 生分解性眼用インプラント及び眼の病気を治療する方法 |
Families Citing this family (338)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6369116B1 (en) * | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
ATE226450T1 (de) * | 1996-03-05 | 2002-11-15 | Robert Gurny | Gepufferte orthoesterpolymere enthaltende arzneimittel |
FR2748205A1 (fr) * | 1996-05-06 | 1997-11-07 | Debio Rech Pharma Sa | Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles |
US5942508A (en) * | 1997-02-04 | 1999-08-24 | Senju Pharmaceutical Co., Ltd. | Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid |
JP2001513369A (ja) * | 1997-08-11 | 2001-09-04 | アラーガン・セイルズ・インコーポレイテッド | 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法 |
US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US20030129215A1 (en) * | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
US7445792B2 (en) * | 2003-03-10 | 2008-11-04 | Abbott Laboratories | Medical device having a hydration inhibitor |
DE19756314C2 (de) * | 1997-12-12 | 2000-06-29 | Roland Bodmeier | Zubereitung mit verlängerter Verweildauer am Applikationsort |
ATE315386T1 (de) * | 1998-08-06 | 2006-02-15 | Joerg Dr Dr Schierholz | Medizinprodukte mit retardierter pharmakologischer aktivität und verfahren zu ihrer herstellung |
EP0985413A1 (de) * | 1998-08-06 | 2000-03-15 | Jörg Michael Dr. Dr. Schierholz | Medizinprodukte mit retardierter pharmakologischer Aktivität und Verfahren zu ihrer Herstellung |
US7455853B2 (en) * | 1998-09-24 | 2008-11-25 | Abbott Cardiovascular Systems Inc. | Medical devices containing rapamycin analogs |
FR2770134B1 (fr) * | 1998-10-28 | 2002-06-07 | Delab | Formulations solides ou semi-solides pour administration locale |
JP2002534139A (ja) * | 1999-01-05 | 2002-10-15 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 網膜と脈絡膜への経強膜徐放性薬剤標的送達 |
US6113638A (en) * | 1999-02-26 | 2000-09-05 | Williams; Lytton A. | Method and apparatus for intervertebral implant anchorage |
US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US7708711B2 (en) * | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US20010049422A1 (en) * | 2000-04-14 | 2001-12-06 | Phaneuf Matthew D. | Methods of applying antibiotic compounds to polyurethane biomaterials using textile dyeing technology |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US6692759B1 (en) * | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
EP1637126B1 (en) * | 2000-07-05 | 2016-12-14 | Allergan, Inc. | Methods for treating inflammation of the eye |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
AR031135A1 (es) | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
US20030082183A1 (en) * | 2000-11-01 | 2003-05-01 | Wheeler Larry A. | Methods and compositions for treatment of ocular neovascularization and neural injury |
WO2002058730A2 (en) * | 2000-11-01 | 2002-08-01 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
BR0115772A (pt) | 2000-11-29 | 2004-01-13 | Oculex Pharm Inc | Processos para a redução ou para a prevenção da rejeição ao transplante ocular e de implantes intraoculares para uso para o mesmo |
EP1550471A1 (en) * | 2000-11-29 | 2005-07-06 | Allergan Inc. | Intraocular implants for preventing transplant rejection in the eye |
KR100446101B1 (ko) * | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
US20020082678A1 (en) * | 2000-12-22 | 2002-06-27 | Motasim Sirhan | Intravascular delivery of mizoribine |
DE60219607T2 (de) * | 2001-01-09 | 2007-12-27 | Microchips, Inc., Bedford | Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US7563255B2 (en) | 2001-05-03 | 2009-07-21 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
US7592016B2 (en) * | 2001-06-28 | 2009-09-22 | Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
GB0116920D0 (en) * | 2001-07-11 | 2001-09-05 | Sulzer Vascutek Ltd | Delivery system |
US20080145402A1 (en) * | 2001-09-10 | 2008-06-19 | Abbott Cardiovascular Systems Inc. | Medical Devices Containing Rapamycin Analogs |
US20030180294A1 (en) * | 2002-02-22 | 2003-09-25 | Devries Gerald W. | Methods of extending corneal graft survival |
CN1638734A (zh) * | 2002-02-22 | 2005-07-13 | 参天制药株式会社 | 微粒结膜下给药的药物释放系统 |
CN1638743B (zh) * | 2002-03-11 | 2012-11-07 | 爱尔康公司 | 可植入药物的释放系统 |
US7074426B2 (en) * | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
WO2003092665A2 (en) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
CA2484512C (en) | 2002-05-17 | 2013-04-16 | Othera Pharmaceuticals, Inc. | Treatment of cataracts and other ophthalmic diseases |
SI1515729T1 (sl) * | 2002-06-13 | 2008-08-31 | Novartis Ag | Kvaternizirane amonij ciklodekstrinske spojine |
ES2295647T3 (es) * | 2002-07-15 | 2008-04-16 | Alcon, Inc. | Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular. |
US20070184089A1 (en) * | 2002-07-15 | 2007-08-09 | Alcon, Inc. | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use |
DE10238310A1 (de) * | 2002-08-21 | 2004-03-04 | Erich Jaeger Gmbh | Elektrodenanordnung |
CZ294328B6 (cs) * | 2002-08-22 | 2004-11-10 | Pliva-Lachema A. S. | Biodegradabilní kompozice s prolongovaným uvolňováním biologicky aktivní látky a způsob její výroby |
EP1536850B1 (en) * | 2002-09-06 | 2016-08-10 | Abbott Laboratories | Medical device having hydration inhibitor |
WO2004028477A2 (en) * | 2002-09-29 | 2004-04-08 | Surmodics, Inc. | Methods for treatment and/or prevention of retinal disease |
US20040221855A1 (en) * | 2002-10-17 | 2004-11-11 | Paul Ashton | Methods for monitoring treatment of disease |
WO2004034975A2 (en) * | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. | Sustained release profile modification |
KR20050085367A (ko) * | 2002-12-04 | 2005-08-29 | 산텐 세이야꾸 가부시키가이샤 | 결막하 데포에 의한 약물 송달 시스템 |
JP2004196787A (ja) * | 2002-12-04 | 2004-07-15 | Santen Pharmaceut Co Ltd | 結膜下デポによるドラッグデリバリーシステム |
US20040137059A1 (en) * | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
EP1594484A2 (en) * | 2003-02-17 | 2005-11-16 | Cipla Ltd. | Pharmaceutical patch |
US8012115B2 (en) | 2003-02-18 | 2011-09-06 | S.K. Pharmaceuticals, Inc. | Optic nerve implants |
US20060167435A1 (en) * | 2003-02-18 | 2006-07-27 | Adamis Anthony P | Transscleral drug delivery device and related methods |
BRPI0407693A (pt) * | 2003-02-20 | 2006-03-01 | Alcon Inc | uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos |
EP1594511A2 (en) * | 2003-02-20 | 2005-11-16 | Alcon, Inc. | Formulations of glucocorticoids to treat pathologic ocular angiogenesis |
US7589107B2 (en) | 2003-05-19 | 2009-09-15 | Othera Holding, Inc. | Amelioration of vitrectomy-induced cataracts |
US7825134B2 (en) * | 2003-05-19 | 2010-11-02 | Othera Holding, Inc. | Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
CA2527121A1 (en) * | 2003-06-13 | 2004-12-29 | Alcon, Inc. | Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis |
US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
WO2006071794A2 (en) | 2004-12-23 | 2006-07-06 | Ethicon Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US8491883B2 (en) * | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
EP1641913B1 (en) * | 2003-06-27 | 2016-01-06 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US7875272B2 (en) * | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
TWI347847B (en) * | 2003-08-20 | 2011-09-01 | Santen Pharmaceutical Co Ltd | Drug delivery system for sub-tenon administration of fine particles |
WO2005037317A2 (en) * | 2003-10-17 | 2005-04-28 | Cornell Research Foundation, Inc. | Mast cell-derived renin |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
US20070224278A1 (en) * | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
US20050130906A1 (en) * | 2003-11-20 | 2005-06-16 | Matier William L. | Amelioration of macular degeneration and other ophthalmic diseases |
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
US20080220049A1 (en) * | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
US8691258B2 (en) * | 2003-12-12 | 2014-04-08 | Medtronic, Inc. | Anti-infective medical device |
WO2005061003A1 (en) * | 2003-12-12 | 2005-07-07 | Medtronic, Inc. | Anti-infective medical device |
JP2007518804A (ja) | 2004-01-20 | 2007-07-12 | アラーガン、インコーポレイテッド | トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物 |
US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
US20070212395A1 (en) * | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US20050244465A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Drug delivery systems and methods for treatment of an eye |
US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
BRPI0510485A (pt) | 2004-04-30 | 2007-11-13 | Allergan Inc | implantes inibidores de tirosina cinase intravìtreos biodegradáveis |
US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US8722097B2 (en) * | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
AU2011213904B2 (en) * | 2004-04-30 | 2014-06-05 | Allergan, Inc. | Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies |
US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
WO2005115375A1 (en) * | 2004-05-25 | 2005-12-08 | Othera Pharmaceuticals, Inc. | Oculoselective drugs and prodrugs |
US20060110428A1 (en) * | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
BRPI0513243B8 (pt) * | 2004-07-12 | 2021-05-25 | Allergan Inc | composições oftálmicas e respectivos usos |
AU2013221985B2 (en) * | 2004-07-12 | 2016-09-01 | Allergan, Inc. | Ophthalmic compositions and methods for treating ophthalmic conditions |
EP1781264B1 (en) | 2004-08-04 | 2013-07-24 | Evonik Corporation | Methods for manufacturing delivery devices and devices thereof |
US20160106717A1 (en) | 2004-09-24 | 2016-04-21 | Gen Pharma Holdings LLC | Cai-based systems and methods for the localized treatment of uveitis |
ES2369554T3 (es) | 2004-09-24 | 2011-12-01 | Rfe Pharma Llc | Carboxi-amido-triazoles para el tratamiento local de enfermedades oculares. |
US20060068012A1 (en) * | 2004-09-29 | 2006-03-30 | Bausch & Lomb Incorporated | Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control |
US20060067978A1 (en) * | 2004-09-29 | 2006-03-30 | Bausch & Lomb Incorporated | Process for preparing poly(vinyl alcohol) drug delivery devices |
WO2006039336A2 (en) | 2004-10-01 | 2006-04-13 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
WO2006043965A1 (en) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
BRPI0518999A2 (pt) | 2004-12-10 | 2008-12-23 | Talima Therapeutics Inc | composiÇÕes e mÉtodos para tratar condiÇÕes da unidade da unha |
US20060275230A1 (en) | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
US20060166361A1 (en) * | 2004-12-21 | 2006-07-27 | Agnieszka Seyda | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
WO2006101548A2 (en) * | 2004-12-21 | 2006-09-28 | Ethicon, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
US20060134174A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
WO2006071778A2 (en) | 2004-12-23 | 2006-07-06 | Ethicon Incorporated | Treatment of parkinson's disease and related disorders using postpartum derived cells |
US20060165810A1 (en) * | 2004-12-28 | 2006-07-27 | The Trustees Of The University Of Pennsylvania | Controlled release from block co-polymer worm micelles |
US20060204548A1 (en) * | 2005-03-01 | 2006-09-14 | Allergan, Inc. | Microimplants for ocular administration |
US20060233858A1 (en) * | 2005-03-08 | 2006-10-19 | Allergan, Inc. | Systems and methods providing targeted intraocular drug delivery |
US8003124B2 (en) * | 2005-04-08 | 2011-08-23 | Surmodics, Inc. | Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease |
US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
US20080312283A1 (en) * | 2005-05-26 | 2008-12-18 | Othera Pharmaceuticals, Inc. | Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts |
BRPI0615962A2 (pt) | 2005-07-27 | 2011-05-31 | Univ Florida | uso de um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lisossomal, um inibidor do trasporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador da resposta a choque térmico, um inibidor de glicosidade, e um inibidor de histona deacetilase, uso de 11-cis-retinal ou 9-cis-retinal e um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lissosomal, um inibidor do transporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador de resposta a choque térmico, um inibidor de glicosidase, e um inibidor de histona deacetilase, método para aumentar a quantidade de um conformação bioquimicamente funcional de uma proteìna em uma célula, composição farmacêutica para o tratamento de um pcd ocular, composição farmacêutica para o tratamento de retinite pigmentosa, kit para o tratamento de um pcd ocular, kit para o tratamento de retinite pigmentosa, método para a identificação de um composto útil para o tratamento de um indivìduo que tem um pcd ocular, método para a identificação de um composto útil para o tratamento de um indivìduo que tem retinite pigmentosa, uso de um inibidor proteassomal ou um inibidor de autofagia e método para a produção de uma proteìna recombinante em uma conformação bioquimicamente funcional |
CA2602440A1 (en) * | 2005-09-16 | 2007-04-05 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
SI1937244T1 (sl) | 2005-09-30 | 2018-12-31 | Io Therapeutics, Llc | Zdravljenje raka s specifičnimi RXR agonisti |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
MX2007012061A (es) | 2005-10-18 | 2007-12-13 | Allergan Inc | Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior. |
WO2007064752A2 (en) | 2005-11-29 | 2007-06-07 | Smithkline Beecham Corporation | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema |
WO2007070870A1 (en) * | 2005-12-16 | 2007-06-21 | Ethicon, Inc. | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
JP5179376B2 (ja) * | 2005-12-19 | 2013-04-10 | エシコン・インコーポレイテッド | ローラーボトルでの分娩後取り出し細胞の体外増殖 |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
SG170789A1 (en) * | 2005-12-28 | 2011-05-30 | Ethicon Inc | Treatment of peripheral vascular disease using postpartum-derived cells |
US7756524B1 (en) | 2006-01-31 | 2010-07-13 | Nextel Communications Inc. | System and method for partially count-based allocation of vocoder resources |
US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
EP1993584B1 (en) | 2006-02-02 | 2012-05-30 | Allergan, Inc. | Inhibitors of CXCR4 activity for use in the treatment of ocular disorders |
US20070203190A1 (en) * | 2006-02-22 | 2007-08-30 | Ghanshyam Patil | Hydroxylamines and derivatives for the inhibition of complement activation |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
US8668676B2 (en) * | 2006-06-19 | 2014-03-11 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US9039761B2 (en) | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
US10669383B2 (en) | 2006-10-31 | 2020-06-02 | Evonik Corporation | Spheronized polymer particles |
US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
US8586556B2 (en) | 2006-11-03 | 2013-11-19 | Allergan, Inc. | Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules |
AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
CA2670990A1 (en) | 2006-12-01 | 2008-06-12 | Allergan, Inc. | Method for determining optimum intraocular locations for drug delivery systems |
US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
CN101687786B (zh) | 2007-02-22 | 2013-05-22 | 奥特拉控股公司 | 羟胺化合物及其用法 |
US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
US20080292680A1 (en) * | 2007-05-14 | 2008-11-27 | Sustained Nano Systems Llc | Hypercompressed polymer particles for controlled release ophthalmic medications |
US8231892B2 (en) * | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
US20080317805A1 (en) * | 2007-06-19 | 2008-12-25 | Mckay William F | Locally administrated low doses of corticosteroids |
WO2009029543A1 (en) * | 2007-08-24 | 2009-03-05 | Aegis Therapeutics, Llc | Controlled release formulations |
US20090123508A1 (en) * | 2007-10-04 | 2009-05-14 | Boston Scientific Scimed, Inc. | Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management |
WO2009046335A1 (en) * | 2007-10-05 | 2009-04-09 | Ethicon, Incorporated | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
EP2197461B1 (en) | 2007-10-08 | 2018-02-21 | Aurinia Pharmaceuticals Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors |
US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
MX2010008874A (es) | 2008-02-14 | 2010-09-22 | Bristol Myers Squibb Co | Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico. |
US9192571B2 (en) | 2008-03-03 | 2015-11-24 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
US8524267B2 (en) * | 2008-04-18 | 2013-09-03 | Warsaw Orthopedic, Inc. | Dexamethasone formulations in a biodegradable material |
CA2723588A1 (en) | 2008-05-12 | 2009-11-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated uses |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US10588855B2 (en) | 2008-05-12 | 2020-03-17 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
CN102099373A (zh) | 2008-05-22 | 2011-06-15 | 百时美施贵宝公司 | 基于纤连蛋白的多价支架结构域蛋白 |
US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
PT2320911E (pt) | 2008-08-01 | 2014-11-11 | Eye Therapies Llc | Composições de vasoconstrição e métodos de utilização |
KR101368736B1 (ko) * | 2008-09-25 | 2014-03-05 | 인비보 테라퓨틱스 코포레이션 | 척수 외상, 염증, 및 면역 질환: 치료제의 국소적 제어 방출 |
US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
US9095506B2 (en) * | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
US8034813B2 (en) * | 2008-11-18 | 2011-10-11 | Bausch & Lomb Incorporated | Polymorphs of brimonidine pamoate |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
CN102387807A (zh) | 2008-12-19 | 2012-03-21 | 先进科技及再生医学有限责任公司 | 肺部疾病和病症的治疗 |
WO2010071863A1 (en) * | 2008-12-19 | 2010-06-24 | Ethicon, Incorporated | Regeneration and repair of neural tissue following injury |
US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
EP2379087B1 (en) * | 2008-12-19 | 2014-08-20 | DePuy Synthes Products, LLC | Umbilical cord tissue derived cells for treating neuropathic pain and spasticity |
US8545554B2 (en) * | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
US20100291182A1 (en) * | 2009-01-21 | 2010-11-18 | Arsenal Medical, Inc. | Drug-Loaded Fibers |
US20100204325A1 (en) * | 2009-02-11 | 2010-08-12 | Allergan, Inc. | Valproic acid drug delivery systems and intraocular therapeutic uses thereof |
WO2010093945A2 (en) | 2009-02-13 | 2010-08-19 | Glaukos Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
US20100239632A1 (en) * | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
US8722034B2 (en) * | 2009-03-26 | 2014-05-13 | Depuy Synthes Products Llc | hUTC as therapy for Alzheimer's disease |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
ES2537385T3 (es) * | 2009-06-09 | 2015-06-08 | Aurinia Pharmaceuticals Inc. | Sistemas de suministro tópico para uso oftálmico |
IN2012DN00352A (ja) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
GB201111485D0 (en) | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
WO2010148352A1 (en) | 2009-06-19 | 2010-12-23 | Altos Vision Limited | Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application |
IN2012DN00407A (ja) * | 2009-08-05 | 2015-08-21 | Pieris Ag | |
US9044580B2 (en) | 2009-08-24 | 2015-06-02 | Arsenal Medical, Inc. | In-situ forming foams with outer layer |
US10420862B2 (en) | 2009-08-24 | 2019-09-24 | Aresenal AAA, LLC. | In-situ forming foams for treatment of aneurysms |
US9173817B2 (en) | 2009-08-24 | 2015-11-03 | Arsenal Medical, Inc. | In situ forming hemostatic foam implants |
US20110202016A1 (en) * | 2009-08-24 | 2011-08-18 | Arsenal Medical, Inc. | Systems and methods relating to polymer foams |
US20120232102A1 (en) | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
WO2011048070A1 (en) | 2009-10-20 | 2011-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis |
US20120322882A1 (en) | 2009-11-09 | 2012-12-20 | Allergan, Inc. | Compositions And Methods For Stimulating Hair Growth |
WO2011075481A1 (en) | 2009-12-16 | 2011-06-23 | Allergan, Inc. | Intracameral devices for sustained delivery |
CN107184544A (zh) | 2010-01-22 | 2017-09-22 | 阿勒根公司 | 前房内持续释放治疗药植入物 |
WO2011106697A1 (en) | 2010-02-25 | 2011-09-01 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
AU2011224445B2 (en) | 2010-03-08 | 2015-08-27 | Spectrum Pharmaceuticals, Inc. | Thioxanthone-based autophagy inhibitor therapies to treat cancer |
AU2011248108B2 (en) | 2010-05-04 | 2016-05-26 | Corium Pharma Solutions, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
ES2566934T3 (es) | 2010-05-10 | 2016-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
WO2011159824A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | Composition and method for treating overactive bladder |
CA2803923A1 (en) | 2010-06-25 | 2011-12-29 | Ignacio R. Rodriguez | Methods of treatment using sterculic acid |
EP2595602B1 (en) | 2010-07-21 | 2018-05-23 | Allergan, Inc. | SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
WO2012024072A1 (en) | 2010-08-19 | 2012-02-23 | Allergan, Inc. | Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition |
EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
EP2661269A1 (en) | 2011-01-03 | 2013-11-13 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases |
US8349005B2 (en) | 2011-01-03 | 2013-01-08 | Masatoshi Murata | Method for burying implant to choroid |
US8968626B2 (en) | 2011-01-31 | 2015-03-03 | Arsenal Medical, Inc. | Electrospinning process for manufacture of multi-layered structures |
US9034240B2 (en) | 2011-01-31 | 2015-05-19 | Arsenal Medical, Inc. | Electrospinning process for fiber manufacture |
US9194058B2 (en) | 2011-01-31 | 2015-11-24 | Arsenal Medical, Inc. | Electrospinning process for manufacture of multi-layered structures |
EP2675491A2 (en) | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013105997A2 (en) | 2011-02-23 | 2013-07-18 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2714016A1 (en) | 2011-06-03 | 2014-04-09 | Allergan, Inc. | Targeted delivery of retinoid compounds to the sebaceous glands |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US9133082B2 (en) | 2011-06-14 | 2015-09-15 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
WO2012177825A1 (en) | 2011-06-21 | 2012-12-27 | Bvw Holding Ag | Medical device comprising boswellic acid |
WO2013011511A1 (en) | 2011-07-18 | 2013-01-24 | Mor Research Applications Ltd. | A device for adjusting the intraocular pressure |
AU2012325341B2 (en) | 2011-10-19 | 2017-01-05 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US8993831B2 (en) | 2011-11-01 | 2015-03-31 | Arsenal Medical, Inc. | Foam and delivery system for treatment of postpartum hemorrhage |
CA2862807A1 (en) | 2011-11-30 | 2013-06-06 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
EP2785178B1 (en) | 2011-12-01 | 2019-05-01 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
CA2858161C (en) | 2011-12-05 | 2020-03-10 | Incept, Llc | Medical organogel processes and compositions |
CN110151745A (zh) | 2011-12-13 | 2019-08-23 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
JP6301263B2 (ja) | 2011-12-23 | 2018-03-28 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | ヒト臍帯組織由来細胞の検出 |
EP2802622A4 (en) * | 2012-01-13 | 2015-08-26 | Univ Missouri | LOW TEMPERATURE PLASMA COATING FOR ANTIBIOFILM FORMATION |
EP2814482A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123275A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123272A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123274A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2900270B1 (en) | 2012-09-26 | 2019-03-06 | Tangent Reprofiling Limited | Combination of benzo(iso)oxazolepiperidines with conjugated linoleic acid |
CN104812397A (zh) * | 2012-09-27 | 2015-07-29 | 阿勒根公司 | 用于持续释放蛋白质的生物可降解的药物递送系统 |
CA2887893C (en) | 2012-10-09 | 2021-07-06 | Douglas SEARS | Therapeutic treatment for attention deficit disorder |
AU2013336683A1 (en) | 2012-10-24 | 2015-05-14 | Biocopea Limited | Drug combinations containing statins for treating cardiovascular diseases |
ES2879430T3 (es) | 2012-11-15 | 2021-11-22 | Apellis Pharmaceuticals Inc | Análogos de compstatina de acción prolongada y composiciones y métodos relacionados |
KR102265808B1 (ko) | 2012-12-21 | 2021-06-16 | 코리움, 인크. | 치료제의 전달을 위한 마이크로어레이 및 그것의 사용방법 |
WO2014108571A2 (en) | 2013-01-14 | 2014-07-17 | Biocopea Limited | Cancer drug and uses |
NZ710444A (en) | 2013-02-11 | 2020-08-28 | Univ California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
EP2956096A1 (en) | 2013-02-15 | 2015-12-23 | Allergan, Inc. | Sustained drug delivery implant |
RS60026B1 (sr) | 2013-02-18 | 2020-04-30 | Vegenics Pty Ltd | Molekuli koji vezuju ligande i njihove upotrebe |
US9890127B2 (en) | 2013-03-11 | 2018-02-13 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
US10981961B2 (en) | 2013-03-11 | 2021-04-20 | University Of Florida Research Foundation, Incorporated | Delivery of card protein as therapy for occular inflammation |
JP6487899B2 (ja) | 2013-03-12 | 2019-03-20 | コリウム インターナショナル, インコーポレイテッド | 微小突起アプリケータ |
EP2967824B1 (en) | 2013-03-12 | 2020-11-04 | Carnegie Mellon University | Coated vaso-occlusive device for treatment of aneurysms |
BR112015022025A8 (pt) | 2013-03-14 | 2019-12-10 | Hallux Inc | composição e uso de um agente ativo |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
WO2014151769A1 (en) | 2013-03-15 | 2014-09-25 | Allergan, Inc. | Compositions including encapsulated isotretinoin and methods for use thereof |
MX2015012933A (es) | 2013-03-15 | 2016-09-19 | Corium Int Inc | Micrordenamiento para suministro de agente terapeutico y metodos de uso. |
WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
EP2994758B1 (en) | 2013-05-08 | 2017-12-20 | Opthea Limited | Biomarkers for age-related macular degeneration (amd) |
CA2922095C (en) | 2013-08-21 | 2021-12-28 | Senseonics, Incorporated | Drug elution for in vivo protection of bio-sensing analytes |
JP6543431B2 (ja) * | 2013-10-10 | 2019-07-10 | ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation | 眼内薬物送達デバイスおよび付随する方法 |
WO2015116709A1 (en) | 2014-01-28 | 2015-08-06 | Allergan, Inc. | Topical retinoid formulations and methods of use |
CA2939219C (en) | 2014-02-11 | 2023-02-28 | Mitokinin Llc | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
EP3132804B1 (en) | 2014-04-17 | 2021-05-05 | Seed Co., Ltd. | Medical device including anionic drug |
EP3148491B1 (en) | 2014-05-29 | 2020-07-01 | Glaukos Corporation | Implants with controlled drug delivery features and manufacturing method for said implants |
WO2016005599A1 (en) | 2014-07-10 | 2016-01-14 | Biocopea Limited | Compositions, methods and uses for treating gender-biased immune disorders |
EP3188714A1 (en) | 2014-09-04 | 2017-07-12 | Corium International, Inc. | Microstructure array, methods of making, and methods of use |
EP3265165B1 (en) | 2015-03-06 | 2020-08-19 | Aerie Pharmaceuticals, Inc. | Implant applicators |
US10857093B2 (en) | 2015-06-29 | 2020-12-08 | Corium, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
CA2993340C (en) | 2015-07-23 | 2024-04-30 | Aerie Pharmaceuticals, Inc. | Intravitreal drug delivery systems for the treatment of ocular conditions |
EP3328886B1 (en) | 2015-07-29 | 2020-09-16 | Allergan, Inc. | Heavy chain only antibodies to ang-2 |
JP2018523673A (ja) | 2015-08-14 | 2018-08-23 | アラーガン、インコーポレイテッドAllergan,Incorporated | Pdgfに対する重鎖のみ抗体 |
US10246436B2 (en) | 2015-09-02 | 2019-04-02 | Trevena, Inc. | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
ES2974107T3 (es) | 2015-10-07 | 2024-06-25 | Apellis Pharmaceuticals Inc | Regímenes de dosificación |
US12048761B2 (en) * | 2015-10-13 | 2024-07-30 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
EP4088719A1 (en) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
WO2017064121A1 (en) | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
AU2016344018B2 (en) | 2015-10-31 | 2019-02-28 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
PT109154B (pt) * | 2016-02-12 | 2019-11-05 | Univ De Coimbra | Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos |
US10835507B2 (en) | 2016-03-10 | 2020-11-17 | Io Therapeutics, Inc. | Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones |
CN115227826A (zh) | 2016-03-10 | 2022-10-25 | Io治疗公司 | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 |
US10883108B2 (en) | 2016-03-31 | 2021-01-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
WO2017184436A1 (en) * | 2016-04-17 | 2017-10-26 | Children's Medical Center Corporation | Systems and methods for steroidal gels |
CN115120405A (zh) | 2016-04-20 | 2022-09-30 | 多斯医学公司 | 生物可吸收眼部药物的递送装置 |
CN109414460A (zh) | 2016-07-05 | 2019-03-01 | 詹森生物科技公司 | 使用祖细胞治疗视网膜血管病 |
EP3484463B1 (en) | 2016-08-19 | 2020-02-12 | The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
WO2018093797A1 (en) | 2016-11-15 | 2018-05-24 | The Schepens Eye Research Institute, Inc. | Compositions and methods for the treatment of aberrant angiogenesis |
CN110520129A (zh) | 2017-02-17 | 2019-11-29 | 特维娜有限公司 | 含有5元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法 |
JP7185633B2 (ja) | 2017-02-17 | 2022-12-07 | トレベナ・インコーポレイテッド | 7員アザ複素環を含有するデルタ-オピオイド受容体調節化合物、その使用方法及び製造方法 |
JP2020516607A (ja) | 2017-04-07 | 2020-06-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. | 投与レジメンならびに関連組成物および方法 |
CA3060956A1 (en) | 2017-05-05 | 2018-11-08 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Ocular applications of matrix bound vesicles (mbvs) |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
WO2018237145A1 (en) | 2017-06-21 | 2018-12-27 | Mitokinin, Inc. | COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE |
WO2019033119A1 (en) | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
WO2019060600A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS |
US11260048B2 (en) | 2017-10-03 | 2022-03-01 | The Schepens Eye Research Institute, Inc. | Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same |
CA3195810A1 (en) | 2017-10-16 | 2022-04-21 | Michael Bruce Horowitz | Clot removal methods and devices with multiple independently controllable elements |
US10172634B1 (en) | 2017-10-16 | 2019-01-08 | Michael Bruce Horowitz | Catheter based retrieval device with proximal body having axial freedom of movement |
US20220104839A1 (en) | 2017-10-16 | 2022-04-07 | Retriever Medical, Inc. | Clot Removal Methods and Devices with Multiple Independently Controllable Elements |
US11739326B2 (en) | 2017-11-14 | 2023-08-29 | Massachusetts Eye And Ear Infirmary | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
JP7356994B2 (ja) | 2018-03-02 | 2023-10-05 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 網膜炎症および神経変性を処置するためのil-34の使用 |
MX2020011535A (es) * | 2018-05-01 | 2020-11-24 | Chibi Inc | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. |
WO2020092897A1 (en) | 2018-11-02 | 2020-05-07 | Senseonics, Incorporated | Drug eluting matrix on analyte indicator |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
US11471426B2 (en) | 2019-10-16 | 2022-10-18 | American River Nutrition, Llc | Compositions comprising quinone and/or quinol and methods of preparations and use thereof |
EP4072521A1 (en) * | 2019-12-10 | 2022-10-19 | Alcon Inc. | Dissolvable polymeric eye inserts with a biodegradable polymer |
WO2021146625A1 (en) | 2020-01-17 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene therapy for treatment of crx-autosomal dominant retinopathies |
US20230226138A1 (en) | 2020-06-01 | 2023-07-20 | Black Cat Bio Limited | Compositions and methods for treating infections and netopathy |
WO2023105417A1 (en) | 2021-12-06 | 2023-06-15 | Breye Therapeutics Aps | Danegaptide formulation for applicatoin in the eye |
AU2022407454A1 (en) | 2021-12-07 | 2024-06-06 | Board Of Regents, The University Of Texas System | Use of an rxr agonist in treating drug resistant her2+ cancers |
WO2023108012A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
US11779553B1 (en) * | 2022-11-28 | 2023-10-10 | Atif B. D. Collins | Methods and devices for treatment of eyelid ptosis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02117A (ja) * | 1987-10-09 | 1990-01-05 | Boehringer Ingelheim Kg | 活性物質放出用の埋込可能な生分解性組成物 |
JPH03170418A (ja) * | 1989-11-22 | 1991-07-24 | Visionex Inc | 生体分解性眼移植片 |
JPH0517370A (ja) * | 1990-11-30 | 1993-01-26 | Senju Pharmaceut Co Ltd | 徐放性眼内埋込み用製剤 |
WO1994005265A1 (en) * | 1992-09-10 | 1994-03-17 | Children's Medical Center Corporation | Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
WO1995013765A1 (en) * | 1993-11-15 | 1995-05-26 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE636865A (ja) * | 1962-08-31 | |||
US3416530A (en) * | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
US3960150A (en) * | 1971-09-09 | 1976-06-01 | Alza Corporation | Bioerodible ocular device |
US3986510A (en) * | 1971-09-09 | 1976-10-19 | Alza Corporation | Bioerodible ocular device |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3914402A (en) * | 1973-06-14 | 1975-10-21 | Alza Corp | Ophthalmic dosage form, for releasing medication over time |
SE390255B (sv) * | 1974-02-18 | 1976-12-13 | N G Y Torphammar | Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon |
US3961628A (en) * | 1974-04-10 | 1976-06-08 | Alza Corporation | Ocular drug dispensing system |
US3921632A (en) * | 1974-08-16 | 1975-11-25 | Frank M Bardani | Implant device |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4180646A (en) * | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
US4144317A (en) * | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
US4063064A (en) * | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4201210A (en) * | 1976-06-22 | 1980-05-06 | The United States Of America As Represented By The Secretary Of Agriculture | Veterinary ocular ring device for sustained drug release |
US4186184A (en) * | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4300557A (en) * | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
US4402979A (en) * | 1980-03-21 | 1983-09-06 | Merck & Co., Inc. & Laboratories | Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid |
US4304765A (en) * | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
JPS58126435U (ja) * | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ttlオ−トストロボ用絞り制御回路 |
US4451254A (en) * | 1982-03-15 | 1984-05-29 | Eli Lilly And Company | Implant system |
US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
DE3220156C2 (de) * | 1982-05-28 | 1990-01-25 | Heida Houston Tex. Thurlow | Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel |
US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4478818A (en) * | 1982-12-27 | 1984-10-23 | Alza Corporation | Ocular preparation housing steroid in two different therapeutic forms |
US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US6217911B1 (en) * | 1995-05-22 | 2001-04-17 | The United States Of America As Represented By The Secretary Of The Army | sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres |
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US5082655A (en) * | 1984-07-23 | 1992-01-21 | Zetachron, Inc. | Pharmaceutical composition for drugs subject to supercooling |
US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
US4966849A (en) * | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
US4640941A (en) * | 1985-11-25 | 1987-02-03 | Alcon Laboratories | Hydrogels containing siloxane comonomers |
DE3612212A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
US4756911A (en) * | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US4863457A (en) * | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US5006342A (en) * | 1986-12-22 | 1991-04-09 | Cygnus Corporation | Resilient transdermal drug delivery device |
US4821210A (en) * | 1987-04-02 | 1989-04-11 | General Electric Co. | Fast display of three-dimensional images |
DE3851152T2 (de) * | 1987-09-03 | 1995-01-26 | Univ Georgia | Cyclosporin-augenmittel. |
US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4945089A (en) * | 1987-12-29 | 1990-07-31 | Alcon Laboratories, Inc. | Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids |
US4865846A (en) * | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
US5004601A (en) * | 1988-10-14 | 1991-04-02 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5034413A (en) * | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
US5028624A (en) * | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
SG49267A1 (en) * | 1989-08-14 | 1998-05-18 | Photogenesis Inc | Surgical instrument and cell isolation and transplantation |
US5112614A (en) * | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
US5268178A (en) * | 1989-09-25 | 1993-12-07 | The Board Of Regents, The University Of Texas System | Biodegradable antibiotic implants and methods of their use in treating and preventing infections |
US5660851A (en) * | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
US5075115A (en) * | 1990-04-02 | 1991-12-24 | Fmc Corporation | Process for polymerizing poly(lactic acid) |
DE69101291T2 (de) * | 1990-08-30 | 1994-07-07 | Senju Pharma Co | Zusammensetzung zur kontrollierten Abgabe von Medikamenten. |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
WO1993000050A1 (en) * | 1991-06-21 | 1993-01-07 | Genetics Institute, Inc. | Pharmaceutical formulations of osteogenic proteins |
US5356629A (en) * | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
US5543154A (en) * | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
US6045791A (en) * | 1992-03-06 | 2000-04-04 | Photogenesis, Inc. | Retinal pigment epithelium transplantation |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
US5384333A (en) * | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
US5700485A (en) * | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
ES2079994B1 (es) * | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
US5314419A (en) * | 1992-10-30 | 1994-05-24 | Pelling George E | Method for dispensing ophthalmic drugs to the eye |
ATE183083T1 (de) * | 1992-11-18 | 1999-08-15 | Fujisawa Pharmaceutical Co | Pharmazeutische zubereitung mit verlängerter wirkung |
TW333456B (en) * | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5707643A (en) * | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
US5456917A (en) * | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
US5393765A (en) † | 1993-12-13 | 1995-02-28 | Hoffmann-La Roche Inc. | Pharmaceutical compositions with constant erosion volume for zero order controlled release |
US6051576A (en) * | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
DE4403326C1 (de) * | 1994-02-03 | 1995-06-22 | Hans Reinhard Prof Dr Koch | Intraokulare Linsenanordnung zur Astigmatismuskorrektur |
US5773021A (en) * | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
US5466233A (en) * | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
US5755785A (en) * | 1994-08-12 | 1998-05-26 | The University Of South Florida | Sutureless corneal transplantation method |
US6063116A (en) * | 1994-10-26 | 2000-05-16 | Medarex, Inc. | Modulation of cell proliferation and wound healing |
CA2149164C (en) * | 1995-05-11 | 2009-03-03 | Zlatko Korunic | Diatomaceous earth insecticidal composition |
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6369116B1 (en) * | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
US5693335A (en) * | 1995-06-07 | 1997-12-02 | Cygnus, Inc. | Skin permeation enhancer composition for use with sex steroids |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US6046187A (en) * | 1996-09-16 | 2000-04-04 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
US5941250A (en) * | 1996-11-21 | 1999-08-24 | University Of Louisville Research Foundation Inc. | Retinal tissue implantation method |
CA2284058C (en) * | 1997-03-31 | 2007-02-20 | Alza Corporation | Diffusional implantable delivery system |
JP2001513369A (ja) * | 1997-08-11 | 2001-09-04 | アラーガン・セイルズ・インコーポレイテッド | 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法 |
US6306426B1 (en) * | 1997-08-11 | 2001-10-23 | Allergan Sales, Inc. | Implant device with a retinoid for improved biocompatibility |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
JP3937533B2 (ja) * | 1997-11-07 | 2007-06-27 | セイコーエプソン株式会社 | 遠隔座標入力装置および遠隔座標入力方法 |
US6329369B1 (en) * | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
WO2000030698A1 (en) * | 1998-11-20 | 2000-06-02 | University Of Connecticut | Apparatus and method for control of tissue/implant interactions |
US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6545182B2 (en) * | 2000-04-13 | 2003-04-08 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US7335803B2 (en) * | 2001-10-19 | 2008-02-26 | Allergan, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
BR0115772A (pt) * | 2000-11-29 | 2004-01-13 | Oculex Pharm Inc | Processos para a redução ou para a prevenção da rejeição ao transplante ocular e de implantes intraoculares para uso para o mesmo |
US6534542B2 (en) * | 2001-02-27 | 2003-03-18 | Allergen Sales, Inc. | (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors |
US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US7386835B1 (en) * | 2002-03-22 | 2008-06-10 | Emc Corporation | Technique for graphical user interface modification |
US6541504B1 (en) * | 2002-04-03 | 2003-04-01 | Allergan Sales, Llc | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
US7276522B2 (en) * | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US20040266776A1 (en) * | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US20040048099A1 (en) * | 2002-08-29 | 2004-03-11 | Chen Jian Ping | Organic light-emitting device using iptycene derivatives |
MXPA05004927A (es) * | 2002-11-06 | 2005-09-08 | Alza Corp | Formulaciones de deposito de liberacion controlada. |
US20040137059A1 (en) * | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US7141597B2 (en) * | 2003-09-12 | 2006-11-28 | Allergan, Inc. | Nonsedating α-2 agonists |
US20050059664A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
US20050058696A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US20050059744A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
JP2007518804A (ja) * | 2004-01-20 | 2007-07-12 | アラーガン、インコーポレイテッド | トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物 |
US7691381B2 (en) * | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US7993634B2 (en) * | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
BRPI0513243B8 (pt) * | 2004-07-12 | 2021-05-25 | Allergan Inc | composições oftálmicas e respectivos usos |
US7357394B2 (en) * | 2004-10-01 | 2008-04-15 | Sri Acquisition Corp. | Modular shooting range |
US20060233857A1 (en) * | 2005-04-14 | 2006-10-19 | Amsden Brian G | Degradable elastomeric network |
US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
-
1995
- 1995-06-02 US US08/459,134 patent/US5869079A/en not_active Expired - Lifetime
-
1996
- 1996-05-31 DK DK04019466.4T patent/DK1477187T3/da active
- 1996-05-31 AT AT96916903T patent/ATE315409T1/de not_active IP Right Cessation
- 1996-05-31 EP EP05027625A patent/EP1637164A3/en not_active Ceased
- 1996-05-31 EP EP04019466A patent/EP1477187B9/en not_active Expired - Lifetime
- 1996-05-31 AU AU59624/96A patent/AU721421B2/en not_active Ceased
- 1996-05-31 CA CA2222889A patent/CA2222889C/en not_active Expired - Fee Related
- 1996-05-31 ES ES96916903T patent/ES2256859T5/es not_active Expired - Lifetime
- 1996-05-31 ES ES04019466T patent/ES2368951T3/es not_active Expired - Lifetime
- 1996-05-31 BR BR9608642A patent/BR9608642A/pt not_active Application Discontinuation
- 1996-05-31 JP JP8536741A patent/JPH11506450A/ja active Pending
- 1996-05-31 DE DE69635734T patent/DE69635734T3/de not_active Expired - Lifetime
- 1996-05-31 CN CN96195703A patent/CN1191492A/zh active Pending
- 1996-05-31 EP EP96916903A patent/EP0831912B2/en not_active Expired - Lifetime
- 1996-05-31 KR KR1019970708691A patent/KR19990022212A/ko not_active Application Discontinuation
- 1996-05-31 CA CA2762921A patent/CA2762921A1/en not_active Abandoned
- 1996-05-31 WO PCT/US1996/008250 patent/WO1996038174A1/en active IP Right Grant
- 1996-05-31 PT PT04019466T patent/PT1477187E/pt unknown
- 1996-05-31 RU RU98100252/14A patent/RU2175561C2/ru active
- 1996-05-31 EP EP10012665A patent/EP2298353A1/en not_active Withdrawn
- 1996-05-31 AT AT04019466T patent/ATE516049T1/de active
- 1996-05-31 PL PL96323747A patent/PL323747A1/xx unknown
- 1996-06-03 MY MYPI96002133A patent/MY132179A/en unknown
- 1996-06-07 TW TW085106878A patent/TW487580B/zh active
-
1998
- 1998-09-24 US US09/160,635 patent/US7048946B1/en not_active Expired - Fee Related
-
2002
- 2002-12-20 US US10/327,018 patent/US20030095995A1/en not_active Abandoned
-
2004
- 2004-09-02 US US10/933,971 patent/US20050048098A1/en not_active Abandoned
-
2005
- 2005-04-29 US US11/117,778 patent/US20050191334A1/en not_active Abandoned
- 2005-11-14 US US11/273,871 patent/US20060067966A1/en not_active Abandoned
-
2006
- 2006-01-30 JP JP2006020891A patent/JP2006192282A/ja not_active Withdrawn
- 2006-05-12 US US11/432,952 patent/US20060204543A1/en not_active Abandoned
-
2007
- 2007-11-01 US US11/933,912 patent/US20080124377A1/en not_active Abandoned
-
2009
- 2009-02-10 US US12/368,807 patent/US20090148499A1/en not_active Abandoned
-
2010
- 2010-10-08 JP JP2010228763A patent/JP2011005300A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02117A (ja) * | 1987-10-09 | 1990-01-05 | Boehringer Ingelheim Kg | 活性物質放出用の埋込可能な生分解性組成物 |
JPH03170418A (ja) * | 1989-11-22 | 1991-07-24 | Visionex Inc | 生体分解性眼移植片 |
JPH0517370A (ja) * | 1990-11-30 | 1993-01-26 | Senju Pharmaceut Co Ltd | 徐放性眼内埋込み用製剤 |
WO1994005265A1 (en) * | 1992-09-10 | 1994-03-17 | Children's Medical Center Corporation | Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
WO1995013765A1 (en) * | 1993-11-15 | 1995-05-26 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
JPH09505300A (ja) * | 1993-11-15 | 1997-05-27 | オキュレックス ファーマシューティカルズ,インコーポレイティド | 生物適合性眼用移植片 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010504822A (ja) * | 2006-09-29 | 2010-02-18 | サーモディクス,インコーポレイティド | 生分解性眼用インプラント及び眼の病気を治療する方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006192282A (ja) | 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物 | |
JP5485314B2 (ja) | 2ヶ月を超える期間の長期持続放出を与えるステロイド眼内インプラント | |
RU2357709C1 (ru) | Микроимплантаты для офтальмологического введения | |
JP5582680B2 (ja) | 生分解性チロシンキナーゼインヒビター硝子体内インプラント | |
ES2661383T3 (es) | Implante ocular biodegradable | |
JP3210328B2 (ja) | 生体分解性眼移植片 | |
WO2000037056A2 (en) | Composition and method for treating glaucoma | |
Deshpande et al. | Bioerodible polymers for ocular drug delivery | |
MXPA97009218A (en) | Improved formulation to control the release of drugs by the combination of hydrophilic and hydrophobic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090929 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100105 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101008 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101228 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110106 |